Sagimet Biosciences
SGMTSagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing a portfolio of fatty acid synthase (FASN) inhibitors.
$441.53M+38.4%
Table of contents
Earnings
Next report
Aug 12, 2026 (In 4 weeks)EPS estimate-$0.28
Competitors
By market cap
By revenue growth
Profile
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing a portfolio of fatty acid synthase (FASN) inhibitors. The company targets dysfunctional metabolic and fibrotic pathways to treat diseases caused by the overproduction of palmitate, such as liver disease and dermatological conditions.
Competitive position
A clinical-stage developer of differentiated FASN inhibitors with a lead candidate targeting the multi-billion dollar MASH market.
GeographiesGlobal
Customer segmentsPatients, Healthcare providers
Business modelR&D intensive, Clinical-stage drug development
SuppliersContract research organizations, Raw material suppliers, Clinical trial sites
CustomersSpecialty pharmacies, Hospitals, Pharmaceutical distributors
CountryUnited States of America
Listed2023
Employees10.0
CEODavid Happel
SectorHealthcare
IndustryBiotechnology
Websitesagimet.com
FilingsSEC EDGAR
Questions, answered.
- What is Sagimet Biosciences's market cap?
- Sagimet Biosciences (SGMT) has a market capitalization of $441.5M and trades on NASDAQ.
- Who are Sagimet Biosciences's competitors?
- Sagimet Biosciences's key competitors include Madrigal Pharmaceuticals, Viking Therapeutics, Biomea Fusion, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Sagimet Biosciences headquartered?
- Sagimet Biosciences is headquartered in United States of America and employs approximately 10 people. It has been publicly traded since 2023.